Sherene Loi, MD· @LoiSher · X·· 1 day agoScore70
Body · original
#ESMO2026
PostMonarch - change to Fulvestrant v placebo with Abema- continues to show better PFS and OS
➡️ results by ESR1 status eagerly awaited!
#ESMOAmbassadors @OncoAlert
Published online in @Annals_Oncology
150 views · 5 likes · 4 reposts · 0 replies
Conference abstracts
1ROmatched by Rapid oral 1: Breast cancer, advanced stage
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.orgSource: Sherene Loi, MD · x.com